Pharmacologic treatment options in patients with thrombocytopenia (Q33332598)

25 July 2017

1 reference

title

Pharmacologic treatment options in patients with thrombocytopenia (English)

1 reference

25 July 2017

1 reference

1 reference

Demetri GD

1

1 reference

25 July 2017

language of work or name

1 reference

1 April 2000

1 reference

25 July 2017

published in

Seminars in Hematology

1 reference

25 July 2017

volume

37

1 reference

25 July 2017

issue

2 Suppl 4

1 reference

25 July 2017

page(s)

11-18

1 reference

Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Diagnosis and treatment of patients refractory to platelet transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Management of alloimmunized, refractory patients in need of platelet transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Case report: fatal Staphylococcus aureus sepsis from single-donor platelet transfusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

A prospective study of symptomatic bacteremia following platelet transfusion and of its management

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Febrile reactions after platelet transfusion: the effect of single versus multiple donors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Is interleukin 3 active in anticancer drug-induced thrombocytopenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Megakaryocyte potentiating activity of IL-1, IL-6 and GM-CSF as evaluated by their action on in vitro human megakaryocytic colonies

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

IL-1 and IL-6 mediate increased production and synthesis by hepatocytes of acute-phase reactant mouse serum amyloid P-component (SAP)

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

The acute phase protein response in patients receiving subcutaneous IL-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced ep

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

cMpl ligand is a humoral regulator of megakaryocytopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Thrombocytopenia in c-mpl-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Purification and characterization of thrombopoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

The potential impact of platelet growth factors in transfusion medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

Treatment of prolonged chemotherapy induced severe thrombocytopenia with recombinant human interleukin-3--a report on four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990048-9

7 January 2021

10.1016/S0037-1963(00)90048-9

Identifiers

DOI

1 reference

25 July 2017

1 reference